SI1261622T1 - Preäśiĺ äśeni rekombinantni hlh s specifiäśno bioaktivnostjo in postopek za njegovo preäśiĺ äśenje - Google Patents

Preäśiĺ äśeni rekombinantni hlh s specifiäśno bioaktivnostjo in postopek za njegovo preäśiĺ äśenje

Info

Publication number
SI1261622T1
SI1261622T1 SI200130709T SI200130709T SI1261622T1 SI 1261622 T1 SI1261622 T1 SI 1261622T1 SI 200130709 T SI200130709 T SI 200130709T SI 200130709 T SI200130709 T SI 200130709T SI 1261622 T1 SI1261622 T1 SI 1261622T1
Authority
SI
Slovenia
Prior art keywords
purification
specific bioactivity
purified recombinant
ion
reverse phase
Prior art date
Application number
SI200130709T
Other languages
English (en)
Slovenian (sl)
Inventor
Gianfranco Paradisi
Mara Rossi
Laura Scaglia
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of SI1261622T1 publication Critical patent/SI1261622T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Semiconductor Lasers (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200130709T 2000-02-22 2001-01-22 Preäśiĺ äśeni rekombinantni hlh s specifiäśno bioaktivnostjo in postopek za njegovo preäśiĺ äśenje SI1261622T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00103692 2000-02-22
EP01907476A EP1261622B1 (en) 2000-02-22 2001-01-22 Purified recombinant hlh having a specific bioactivity and process for purification thereof
PCT/EP2001/000666 WO2001062774A2 (en) 2000-02-22 2001-01-22 Purified lh

Publications (1)

Publication Number Publication Date
SI1261622T1 true SI1261622T1 (sl) 2007-06-30

Family

ID=8167926

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130709T SI1261622T1 (sl) 2000-02-22 2001-01-22 Preäśiĺ äśeni rekombinantni hlh s specifiäśno bioaktivnostjo in postopek za njegovo preäśiĺ äśenje

Country Status (30)

Country Link
US (2) US7053054B2 (cg-RX-API-DMAC7.html)
EP (2) EP1261622B1 (cg-RX-API-DMAC7.html)
JP (1) JP4959898B2 (cg-RX-API-DMAC7.html)
KR (1) KR100808149B1 (cg-RX-API-DMAC7.html)
CN (1) CN100480258C (cg-RX-API-DMAC7.html)
AT (1) ATE356138T1 (cg-RX-API-DMAC7.html)
AU (1) AU780377B2 (cg-RX-API-DMAC7.html)
BG (1) BG65761B1 (cg-RX-API-DMAC7.html)
BR (2) BR122012018280B8 (cg-RX-API-DMAC7.html)
CA (1) CA2399100C (cg-RX-API-DMAC7.html)
CY (1) CY1108056T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303274B6 (cg-RX-API-DMAC7.html)
DE (1) DE60127100T2 (cg-RX-API-DMAC7.html)
DK (1) DK1261622T3 (cg-RX-API-DMAC7.html)
EA (1) EA004385B1 (cg-RX-API-DMAC7.html)
EE (1) EE04932B1 (cg-RX-API-DMAC7.html)
ES (1) ES2278722T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20020651B1 (cg-RX-API-DMAC7.html)
HU (1) HU227007B1 (cg-RX-API-DMAC7.html)
IL (2) IL151309A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02007867A (cg-RX-API-DMAC7.html)
NO (1) NO328693B1 (cg-RX-API-DMAC7.html)
PL (1) PL207728B1 (cg-RX-API-DMAC7.html)
PT (1) PT1261622E (cg-RX-API-DMAC7.html)
RS (1) RS50416B (cg-RX-API-DMAC7.html)
SI (1) SI1261622T1 (cg-RX-API-DMAC7.html)
SK (1) SK287041B6 (cg-RX-API-DMAC7.html)
UA (2) UA92145C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001062774A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200206108B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020651B1 (en) * 2000-02-22 2011-01-31 Laboratoires Serono Sa Purified lh
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
DE602004030546D1 (de) * 2003-03-04 2011-01-27 Aspenbio Pharma Inc LH zur Verwendung der Erhaltung einer oder mehreren Schwangerschaften durch Induktion der Bildung des sekundären Gelbkörpers.
CN1283792C (zh) * 2003-11-14 2006-11-08 余伟明 生物大分子组分相分离法
ATE446314T1 (de) * 2003-12-22 2009-11-15 Ares Trading Sa Methode zur reinigung von fsh
ATE469912T1 (de) * 2004-10-04 2010-06-15 Novetide Ltd Gegenionenaustauschverfahren für peptide
EP1809663B1 (en) * 2004-11-09 2008-09-17 Ares Trading S.A. Method for purifying fsh
US20080219952A1 (en) * 2005-08-26 2008-09-11 Ares Trading S.A. Process For the Preparation of Glycosylated Interferon Beta
JP5199112B2 (ja) * 2005-12-09 2013-05-15 アレス トレーディング ソシエテ アノニム Fsh又はfsh変異体を精製するための方法
EP2203465A1 (en) * 2007-10-22 2010-07-07 Merck Serono S.A. Method for purifying an fc-containing protein
CA2702448A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying fc-fusion proteins
CN101928342B (zh) * 2009-06-18 2013-05-08 上海天伟生物制药有限公司 一种高纯度绝经期促性腺素及其制备方法和用途
WO2015168622A1 (en) * 2014-05-01 2015-11-05 Virginia Tech Intellectual Properties, Inc. Keratin nanomaterials and methods of production
CN104569441B (zh) * 2015-01-19 2016-02-03 成都大熊猫繁育研究基地 大熊猫尿液促黄体素的酶联检测方法及其应用
CA3140267A1 (en) 2019-05-16 2020-11-19 Ceva Sante Animale Compositions and methods for increasing reproduction performance in non-human mammals using recombinant luteinizing hormone

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002757A1 (en) * 1988-09-02 1990-03-22 Integrated Genetics, Inc. Heteropolymeric protein
DE122010000006I2 (de) * 1989-02-21 2012-06-21 Univ Washington Modifizierte formen von fortpflanzungshormonen.
US5087615A (en) * 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
IT1287138B1 (it) * 1996-11-07 1998-08-04 Ibsa Inst Biochimique Sa Procedimento per la separazione e purificazione di fsh e lh
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
AU747179B2 (en) * 1997-06-25 2002-05-09 Merck Serono Sa Disulfide cross-linked glycoprotein hormone analogs, their preparation and use
HRP20020651B1 (en) * 2000-02-22 2011-01-31 Laboratoires Serono Sa Purified lh

Also Published As

Publication number Publication date
HUP0301814A3 (en) 2004-10-28
ZA200206108B (en) 2003-07-31
NO20023963L (no) 2002-08-20
UA92145C2 (en) 2010-10-11
YU60302A (sh) 2005-09-19
AU780377B2 (en) 2005-03-17
HRP20020651B1 (en) 2011-01-31
EP1777231A2 (en) 2007-04-25
JP4959898B2 (ja) 2012-06-27
HU227007B1 (en) 2010-04-28
EP1777231A3 (en) 2007-11-07
ES2278722T3 (es) 2007-08-16
KR100808149B1 (ko) 2008-02-29
WO2001062774A3 (en) 2002-03-14
BG65761B1 (bg) 2009-10-30
PT1261622E (pt) 2007-04-30
AU3543601A (en) 2001-09-03
HUP0301814A2 (hu) 2003-08-28
KR20030001358A (ko) 2003-01-06
EP1261622A2 (en) 2002-12-04
CY1108056T1 (el) 2013-09-04
BRPI0108553B8 (pt) 2021-05-25
EA004385B1 (ru) 2004-04-29
EE200200464A (et) 2003-12-15
HRP20020651A2 (en) 2004-12-31
DE60127100D1 (de) 2007-04-19
MXPA02007867A (es) 2003-02-10
SK287041B6 (sk) 2009-10-07
SK12052002A3 (sk) 2002-12-03
HK1052014A1 (zh) 2003-08-29
US20030186893A1 (en) 2003-10-02
IL151309A0 (en) 2003-04-10
BR122012018280B1 (pt) 2018-01-09
CN1404486A (zh) 2003-03-19
PL362891A1 (en) 2004-11-02
BR122012018280B8 (pt) 2021-05-25
NO328693B1 (no) 2010-04-26
RS50416B (sr) 2009-12-31
UA78676C2 (en) 2007-04-25
US7053054B2 (en) 2006-05-30
CA2399100A1 (en) 2001-08-30
CZ20022856A3 (cs) 2003-01-15
ATE356138T1 (de) 2007-03-15
NO20023963D0 (no) 2002-08-20
EA200200893A1 (ru) 2003-02-27
DK1261622T3 (da) 2007-05-29
CN100480258C (zh) 2009-04-22
PL207728B1 (pl) 2011-01-31
CZ303274B6 (cs) 2012-07-11
US20060079460A1 (en) 2006-04-13
CA2399100C (en) 2011-11-08
BG107001A (bg) 2003-04-30
EE04932B1 (et) 2007-12-17
BR0108553A (pt) 2003-12-23
EP1261622B1 (en) 2007-03-07
JP2003532636A (ja) 2003-11-05
IL151309A (en) 2010-11-30
DE60127100T2 (de) 2007-06-28
BRPI0108553B1 (pt) 2016-06-14
WO2001062774A2 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
PL362891A1 (en) Purified lh
HU1300063D0 (hu) Tisztított hCG
WO1997032607A3 (en) Activated linkers and methods for making and purifying the same
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
MXPA01010522A (es) Composiciones de gonadotropina altamente purificada y procedimiento para prepararlas.
ES2161790T3 (es) Procedimiento de separacion y de purificacion de proteinas dependientes de la vitamina k.
KR900001854A (ko) 환원형의 비글리코실화 재조합 인체 il₂, 그의 제조방법 및 의약품으로서의 용도
Hooper et al. Histone III: II. ISOLATION AND SEQUENCES OF CHYMOTRYPTIC PEPTIDES FROM CALF THYMUS HISTONE III
Hocart et al. Improved antagonists of luteinizing hormone-releasing hormone modified in position 7
ES2055875T3 (es) Procedimiento de fabricacion del factor antihemofilico (fviiic) con una pureza muy elevada.
Tsuda et al. Identification of secretin diastereoisomers produced during synthesis